Skip to main content

Table 2 MGFA PIS and MGSTI at last follow up

From: Outcome measures and treatment effectiveness in late onset myasthenia gravis

MGFA-PIS  
Type of MG CSR/ MM-0 MM-1 MM-2 MM-3 PR Symptomatic Total
  Ocular 4 (11,1%) 6 (16,7%) 9 (25%) 3 (8,3%) 13 (36,1%) 1 (2,8%) 36
  EOMG 1 (2,5%) 5 (12,5%) 1 (2,5%) 15 (37,5%) 16 (42,5%) 2 (5%) 40
  LOMG 3 (4,2%) 5 (6,9%) 5 (6,9%) 23 (31,9%) 32 (45,8%) 4 (5,6%) 72
  Thymoma 1 (4,0%) 1 (4,0%) 7 (28%) 13 (52%) 3 (12%) 25
  Sieronegative 1 (4,8%) 5 (23,8%) 3 (14,3%) 5 (23,8%) 7 (33,3%) - 21
  Anti-MUSK - 2 (14,3%) - 1 (7,1%) 9 (64,2%) 2 (9,5%) 14
  Total 10 (4,8%) 24 (11,5%) 18 (8,7%) 54 (26%) 90 (44,2%) 12 (5,8%) 208
MGSTI  
Type of MG 0 1 2 3 4 5 6 Total
  Ocular 16 (44,4%) 9 (25%) 9 (25%) 1 (2,8%) 1 (2,8%)    36
  EOMG 2 (5,0%) 7 (17,5%) 16 (40%) 13 (32,5%)   2 (5,0%)   40
  LOMG 11 (15,3%) 20 (27,8%) 26 (36,1%) 11 (15,3%) 1 (1,4%) 2 (2,8%) 1 (1,4%) 72
  Thymoma 1 (4,0%) 7 (28,0%) 13 (52,0%) 1 (4,0%)   2 (8,0%) 1 (4,0%) 25
  Sieronegative 7 (30,4%) 3 (13,0%) 6 (26,1%) 4 (17,4%)     23
  Anti-MUSK   2 (14,3%) 8 (57,1%) 2 (14,3%)   2 (14,3%)   14
  Total 37 (17,9%) 48 (23,2%) 78 (37,5%) 32 (15,5) 2 (1,0%) 8 (3,9%) 2 (1,0%) 208
  1. Abbreviations: CSR Complete stable remission, EOMG Early onset myasthenia gravis, LOMG Late onset myasthenia gravis, MM Minimal manifestations, MUSK Muscle specific tyrosine kinase, PR Pharmacologic remission